CAS 928659-70-5
:Eliglustat tartrate
Description:
Eliglustat tartrate is a synthetic compound primarily used as a pharmacological agent in the treatment of Gaucher disease, a genetic disorder resulting from the deficiency of the enzyme glucocerebrosidase. It functions as a substrate reduction therapy, inhibiting the synthesis of glucosylceramide, thereby reducing its accumulation in cells. The substance is characterized by its molecular formula, which reflects its complex structure, and it typically appears as a white to off-white powder. Eliglustat tartrate is soluble in water and exhibits stability under standard storage conditions. Its mechanism of action involves selective inhibition of glucosylceramide synthase, which is crucial for its therapeutic efficacy. The compound is administered orally and has a favorable pharmacokinetic profile, allowing for once-daily dosing. As with any medication, potential side effects may include gastrointestinal disturbances and other systemic reactions, necessitating monitoring during treatment. Overall, Eliglustat tartrate represents a significant advancement in the management of Gaucher disease, providing an alternative to enzyme replacement therapy.
Formula:C23H36N2O4C4H6O6
InChI:InChI=1S/C23H36N2O4.C4H6O6/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t19-,23-;1-,2-/m11/s1
InChI key:InChIKey=VNGQLUTVKDPUJS-VUBSCCJGSA-N
SMILES:[C@@H]([C@@H](CN1CCCC1)NC(CCCCCCC)=O)(O)C=2C=C3C(=CC2)OCCO3.[C@@H]([C@H](C(O)=O)O)(C(O)=O)O
Synonyms:- Eliglustat hemitartrate
- Octanamide, N-[(1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (2:1)
- Eliglustat tartrate
- Genz 112638
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Eliglustat hemitartrate
CAS:Eliglustat hemitartrate (Genz-112638) , with an IC50 of 24 nM, is a specific, potent, oral active glucocerebral glycosidase inhibitor.Formula:C50H78N4O14Purity:99.17% - 99.96%Color and Shape:White SolidMolecular weight:959.17Eliglustat hemitartrate
CAS:Eliglustat hemitartrateFormula:C25H39N2O7Purity:99.5%Molecular weight:479.59Eliglustat hemitartrate
CAS:Formula:C50H78N4O14Purity:98%Color and Shape:SolidMolecular weight:959.1727Eliglustat Tartrate
CAS:Controlled ProductFormula:(C23H36N2O4)•(C4H6O6)Color and Shape:NeatMolecular weight:2404.541501N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide ((2R,3R)-2,3-dihydroxysuccinate)(2:1)
CAS:N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide ((2R,3R)-2,3-dihydroxysuccinate)(2:1)Formula:C50H78N4O14Purity:98%Molecular weight:959.17Eliglustat hemitartrate
CAS:Eliglustat hemitartrate is a drug that inhibits the enzyme glucosylceramide synthase, which is involved in the production of glucosylceramide. Eliglustat hemitartrate is used to treat Gaucher disease, a rare genetic disorder where fatty substances accumulate in the liver and spleen. Eliglustat hemitartrate has been shown to reduce the levels of glucosylceramide in patients with Gaucher disease and may be an effective treatment for this condition. It also has been shown to inhibit P-glycoprotein (P-gp), which may allow more eliglustat to enter cells.
Formula:C50H78N4O14Purity:Min. 98 Area-%Color and Shape:PowderMolecular weight:959.17 g/mol
